Active ingredientElacestrantCat. No. P-E016-001CAS 722533-56-4Family · Pharmaceutical analytical standards
Elacestrant
A selective oestrogen receptor degrader (SERD), approved in 2023 in the United States and the European Union for advanced ER-positive breast cancer with ESR1 gene mutations. This family brings together the active ingredient and other impurities.
Did you know?It was the first SERD taken by mouth to be approved by the FDA: the founder of the class, fulvestrant, is given by intramuscular injection.
Go to the active ingredient →Active ingredientElacestrantCat. No. P-E016-001CAS 722533-56-4
Active ingredientElacestrant DihydrochlorideCat. No. P-E016-002CAS 1349723-93-8
Impurity(S)-ElacestrantCat. No. P-E016-003CAS 2309762-29-4
ImpurityElacestrant Impurity 1Cat. No. P-E016-004CAS 3033111-52-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.